The Most-Validated Secretagogue

Most GH secretagogues live in the preclinical or off-label research world. Tesamorelin is the exception: it carries an FDA approval for reducing excess visceral abdominal fat in HIV-associated lipodystrophy, backed by placebo-controlled Phase 3 trials that measured visceral adipose tissue directly with CT scans.

That trial evidence is the key differentiator. The pivotal studies showed significant visceral fat reduction and improvements in triglycerides and hepatic fat — without the subcutaneous fat loss characteristic of exogenous GH. For members who weight clinical validation heavily, tesamorelin is the most defensible choice in the secretagogue category. The thread below is where members discuss the evidence in detail.